Tretinoin and Apixaban Interaction: What the Evidence Actually Shows
HealthRX.com
No established interaction between tretinoin cream and apixaban
Key numbers
- 99%Rise in apixaban AUC with ketoconazole 400 mg daily in 18 healthy adults (oral inhibitor)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 54%Drop in oral apixaban AUC with rifampin 600 mg daily in 20 healthy participants (oral inducer)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- less than 2%Share of applied tretinoin cream absorbed through skin in healthy men, single or repeated useSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1% to 31%Range of tretinoin absorption across topical formulations and skin conditionsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
FDA adverse event reports listing both apixaban and tretinoin
Through 2026-10-28, FDA had received 154 adverse event reports that list both apixaban and tretinoin, out of 278,760 reports for apixaban and 8,546 for tretinoin. A joint report shows both were recorded for the same person, not that they interacted.
| Measure | Value |
|---|---|
| Reports listing both drugs | 154 |
| All reports for apixaban | 278,760 |
| All reports for tretinoin | 8,546 |
| Joint reports naming acute kidney injury | 22 |
| Joint reports naming diarrhoea | 20 |
| Joint reports naming skin discolouration | 10 |
| Joint reports naming differentiation syndrome | 9 |
How this was calculated
Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.
Reports listing both apixaban and tretinoin as single-ingredient active substances, any brand, suspect or concomitant
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.
At a glance
- Listed interaction / None in the Renova tretinoin label [2]
- Tretinoin absorption / Under 2% of an applied 0.05% cream dose; 1% to 31% across formulations and skin conditions [2]
- Apixaban elimination / Multiple pathways; non-renal routes are CYP3A4 metabolism and direct intestinal excretion, and it is a P-gp substrate [1][3]
- Apixaban exposure, inhibitors / Ketoconazole raised AUC 99% and peak concentration 62% in 18 healthy adults [1]
- Apixaban exposure, inducers / Rifampin cut oral AUC 54% in 20 healthy adults [3]
- Bleeding / Apixaban can cause serious bleeding. Its boxed warning addresses the risk of blood clots after premature discontinuation and the risk of spinal or epidural hematomas [4]
- Oral tretinoin (ATRA) / A separate product used in acute promyelocytic leukemia; cream absorption data do not describe it [5]
- Bottom line / The Renova label lists topical irritants and photosensitizers, not apixaban; apixaban itself carries established bleeding risks [2][4]
Does the tretinoin label list apixaban?
The Renova (tretinoin cream 0.02%) prescribing information has a drug interactions section that names the topical products which increase irritation — medicated or abrasive soaps, shampoos and cleansers, high-alcohol products, astringents, spices, waxes and depilatories — and the drugs known to be photosensitizers, such as thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides [2]. It does not name apixaban, or any other anticoagulant.
On the apixaban side, the documented pharmacokinetic interactions involve combined P-glycoprotein and strong CYP3A4 inhibitors and inducers [1][3], and drugs that affect hemostasis — aspirin and other antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs — add to its bleeding risk [4].
How much tretinoin actually reaches the bloodstream?
The Renova label reports absorption for a 0.05% oil-in-water tretinoin cream, not for Renova 0.02% itself. With radiolabeled cream, absorption was less than 2% of the applied dose in seven healthy men after a single application and in seven men after 28 days of daily application, and the extent of bioavailability was lower after repeated application [2]. No significant difference in endogenous tretinoin concentrations was seen between single and repeated daily application [2]. No percutaneous absorption study was run with Renova 0.02% [2].
The same label section gives a wider figure: transdermal absorption of tretinoin from various topical formulations ranged from 1% to 31% of the applied dose, depending on whether it was applied to healthy or dermatitic skin [2].
Where apixaban interactions actually come from
Apixaban is eliminated by multiple pathways, renal and non-renal; the non-renal routes are CYP3A4 metabolism and direct intestinal excretion, and the drug is a P-glycoprotein substrate [1][3]. Adding a strong dual CYP3A4 and P-gp inhibitor roughly doubles exposure. In 18 healthy subjects, ketoconazole 400 mg daily raised apixaban area under the curve by 99% and peak concentration by 62% [1]. Diltiazem 360 mg daily, a moderate CYP3A4 inhibitor that also inhibits P-gp, raised AUC by 40% and peak concentration by 31% [1].
In the other direction, rifampin 600 mg daily in 20 healthy participants lowered oral apixaban AUC by 54% and reduced bioavailability from 49% to 39% [3].
Real-world data point the same way. In a Belgian nationwide cohort of 193,072 patients with atrial fibrillation on a DOAC, concomitant P-gp/CYP3A4 inhibitors were associated with more major bleeding (adjusted hazard ratio 1.24, 95% CI 1.18-1.30) and inducers with more stroke (adjusted hazard ratio 1.31, 95% CI 1.03-1.68); among apixaban users the major bleeding hazard ratio was 1.27 (95% CI 1.16-1.39) [6]. These are observational associations.
In the ketoconazole, diltiazem and rifampin studies, participants received those drugs orally [1][3]; those studies did not test topical tretinoin.
Oral tretinoin for leukemia is a different product
Oral tretinoin, all-trans retinoic acid or ATRA, is used in the treatment of acute promyelocytic leukemia. The European LeukemiaNet guidance on that disease covers complications including differentiation syndrome, QT prolongation, and other ATRA- and arsenic trioxide-related toxicities [5]. The absorption figures from a 0.05% cream do not describe oral tretinoin.
What to watch for on apixaban itself
The Eliquis label carries a boxed warning in two parts: stopping an oral anticoagulant early, for a reason other than pathological bleeding or completing therapy, raises the risk of thrombotic events; and spinal or epidural hematomas can occur with neuraxial anesthesia or spinal puncture, with a higher risk when NSAIDs, platelet inhibitors or other anticoagulants are used at the same time [4]. The label also states that aspirin and other antiplatelets, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs add to bleeding risk [4]. In the ARISTOTLE trial of 18,201 patients with atrial fibrillation, major bleeding occurred at 2.13 per 100 patient-years on apixaban versus 3.09 on warfarin (hazard ratio 0.69, 95% CI 0.60-0.80) [7].
Tretinoin's labeled effects are local to the skin: peeling, dry skin, burning, stinging, erythema and itching. In double-blind, vehicle-controlled studies involving 339 patients who applied Renova 0.02% to their faces, skin irritation that was severe, led to temporary discontinuation, or led to use of a mild topical corticosteroid was reported in 32% of patients, and about 4% discontinued use because of adverse reactions [2]. The Renova label also says exposure to sunlight, including sunlamps, should be avoided or minimized, and recommends sunscreens with a minimum SPF of 15 and protective clothing [2].
Bottom line
The Renova 0.02% label does not list apixaban [2]. Apixaban exposure shifts substantially with strong oral CYP3A4/P-gp inhibitors and inducers [1][3], and it has a known bleeding risk that several other drugs increase [4].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Can topical tretinoin be used with apixaban?
Is oral tretinoin the same as tretinoin cream?
Which drugs actually change apixaban levels?
Does apixaban need INR checks or a vitamin K diet?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What are the potential drug-drug interactions with apixaban?
Apixaban's documented pharmacokinetic interactions involve combined P-glycoprotein and strong CYP3A4 inhibitors and inducers, such as ketoconazole and rifampin. Drugs that affect hemostasis, including aspirin, other antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs, add to its bleeding risk. Diltiazem, a moderate CYP3A4 inhibitor that also inhibits P-gp, raised apixaban AUC by 40% in 18 healthy subjects.
Can I take DULoxetine and apixaban together?
Duloxetine is an SNRI, and the Eliquis label says SNRIs add to apixaban's bleeding risk. No interaction figures for duloxetine with apixaban are given, and no prohibition on combining the two is stated.
References
Show all 7 referencesHide references
- Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838-46.
- U.S. National Library of Medicine, DailyMed. Renova tretinoin cream 0.02% (Bausch) prescribing information. Renova tretinoin cream 0.02% (Bausch) label
- Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119-27.
- Drugs@FDA: FDA-Approved Drugs.
- Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630-1643.
- Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722-730.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.